Pruriticpapulareruption of HIV (Human Immunodeficiency Virus) is the most common rash associated with HIV infection, and is often the presenting sign in an otherwise asymptomatic HIV-positive person.
Who gets pruritic papular eruption of HIV?
Pruritic papular eruption (PPE) of HIV affects 11–46% of patients with HIV, including children. The prevalence varies with geographic location and is most common in the tropics and subtropical areas.
Most studies report a female predominance.
PPE of HIV is the presenting symptom of HIV in 25–79% of cases. It is classified as WHO Stage 2 HIV disease. It is reported to be a skin sign of advanced HIV, being three times more common when the CD4 lymphocyte count is less than 200 x109/L.
What causes pruritic papular eruption of HIV?
Currently the cause has not been identified. Medications, autoimmunity, and direct HIV infection of the skin have been considered but not proven. An exaggerated immune response to insect bites is supported by the geographic distribution, clinical and histological features, and increased IgE and eosinophils in the blood.
What are the clinical features of pruritic papular eruption of HIV?
Pruritic papular eruption of HIV presents as a very itchy chronic rash:
Small, red, intensely itchy, firm papules
Induce scratching
Evolve into hyperpigmentedmacules and nodules
Most common on exposed skin, particularly the extremities
Sparing of mucous membranes, palms and soles, and web spaces.
Effective highly active antiretroviral therapy (HAART) has been reported in case series to provide not only symptomatic relief of itch, but also resolution of PPE of HIV lesions without recurrence in the majority of patients.
What is the outcome for pruritic papular eruption of HIV?
Untreated, pruritic papular eruption of HIV is persistent.
Bibliography
Budavari JM, Grayson W. Papular follicular eruptions in human immunodeficiency virus-positive patients in South Africa. Int J Dermatol. 2007;46(7):706–10. doi:10.1111/j.1365-4632.2007.03141.x. PubMed
Castelnuovo B, Byakwaga H, Menten J, Schaefer P, Kamya M, Colebunders R. Can response of a pruritic papular eruption to antiretroviral therapy be used as a clinical parameter to monitor virological outcome?. AIDS. 2008;22(2):269–73. doi:10.1097/QAD.0b013e3282f313a9. Journal
Chua SL, Amerson EH, Leslie KS, et al. Factors associated with pruritic papular eruption of human immunodeficiency virus infection in the antiretroviral therapy era. Br J Dermatol. 2014;170(4):832–9. doi:10.1111/bjd.12721. Journal
Mohammed S, Vellaisamy SG, Gopalan K, Sukumaran L, Valan AS. Prevalence of pruritic papular eruption among HIV patients: a cross-sectional study. Indian J Sex Transm Dis AIDS. 2019;40(2):146–51. doi:10.4103/ijstd.IJSTD_69_18. Journal
Samanta M, Kundu C, Sarkar M, Bhattacharyya S, Chatterjee S. Papular pruritic eruptions: a marker of progressive HIV disease in children: experience from eastern India. Indian J Sex Transm Dis AIDS. 2009;30(2):79–83. doi:10.4103/0253-7184.62762. PubMed Central